BGIM
ANIP icon

Brandywine Global Investment Management’s ANI Pharmaceuticals ANIP Stock Holding History

Brandywine Global Investment Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-100,899
Closed -$5.9M – 563
2024
Q3 		$5.9M Sell
100,899
-6,411
-6% -$391K 0.04% 367
2024
Q2 		$6.83M Sell
107,310
-7,761
-7% -$504K 0.05% 335
2024
Q1 		$7.95M Sell
115,071
-18,349
-14% -$1.11M 0.06% 318
2023
Q4 		$7.36M Buy
133,420
+425
+0.3% +$23.4K 0.06% 311
2023
Q3 		$7.72M Sell
132,995
-1,576
-1% -$91K 0.07% 285
2023
Q2 		$7.24M Buy
134,571
+4,718
+4% +$209K 0.06% 304
2023
Q1 		$5.16M Buy
129,853
+2,185
+2% +$92.1K 0.04% 377
2022
Q4 		$5.14M Buy
127,668
+17,933
+16% +$674K 0.04% 372
2022
Q3 		$3.53M Buy
109,735
+22,138
+25% +$758K 0.03% 424
2022
Q2 		$2.6M Sell
87,597
-9,467
-10% -$273K 0.02% 482
2022
Q1 		$2.73M Sell
97,064
-30
-0% -$1.12K 0.02% 494
2021
Q4 		$4.47M Buy
97,094
+83,754
+628% +$3.6M 0.03% 422
2021
Q3 		$438K Sell
13,340
-200
-1% -$6.22K ﹤0.01% 604
2021
Q2 		$475K Sell
13,540
-1,100
-8% -$37.4K ﹤0.01% 602
2021
Q1 		$529K Sell
14,640
-200
-1% -$6.26K ﹤0.01% 586
2020
Q4 		$431K Buy
14,840
+164
+1% +$4.7K ﹤0.01% 563
2020
Q3 		$415K Buy
14,676
+2,200
+18% +$65.5K ﹤0.01% 524
2020
Q2 		$404K Buy
12,476
+200
+2% +$7.17K ﹤0.01% 546
2020
Q1 		$501K Buy
12,276
+88
+0.7% +$4.68K 0.01% 555
2019
Q4 		$733K Buy
12,188
+2,588
+27% +$171K 0.01% 578
2019
Q3 		$700K Hold
9,600
– – 0.01% 581
2019
Q2 		$790K Buy
9,600
+6,800
+243% +$484K 0.01% 584
2019
Q1 		$198K Buy
+2,800
New +$165K ﹤0.01% 635

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Brandywine Global Investment Management's ANIP Position: Q4 2024 in Review

Brandywine Global Investment Management sold out of ANI Pharmaceuticals (ANIP) in Q4 2024, closing a stake of 100,899 shares — an estimated $5.9M sold.

Brandywine Global Investment Management first reported a position in ANIP in Q1 2019 and held it in 23 quarters. The position peaked at $7.95M in Q1 2024. 205 funds tracked by Wall St. Rank hold ANIP as of Q4 2024.

  • Brandywine Global Investment Management reported no remaining ANI Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Brandywine Global Investment Management sold 100,899 ANI Pharmaceuticals shares in Q4 2024, an estimated $5.9M.
  • Brandywine Global Investment Management first reported a position in ANI Pharmaceuticals in Q1 2019 and held it in 23 quarters.
  • Brandywine Global Investment Management's ANI Pharmaceuticals position peaked at $7.95M in Q1 2024.
  • 205 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2024.

Based on Brandywine Global Investment Management's 13F filing for Q4 2024, filed 12 Feb 2025.